Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma

Published:2024-02-29 Issue:4 Volume:65 Page:586-592
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Lin Fanching,Clift Renee,Ehara Takeru,Yanagida Hayato,Horton Steven,Noncovich Alain,Guest Matt,Kim Daniel,Salvador Katrina,Richardson Samantha,Miller Terra,Han Guangzhou,Bhat Abhijit,Song Kenneth,Li Gary

Publisher

Society of Nuclear Medicine

Reference51 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology;Eslam;Nat Rev Gastroenterol Hepatol.,2020

3. Glypicans

4. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

5. Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma;Bell;Molecules.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [⁶⁸Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series;Journal of Nuclear Medicine;2024-09-12

2. Trends in cancer imaging;Trends in Cancer;2024-09

3. Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma;EJNMMI Research;2024-08-22

4. Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma;2024-06-27

5. Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation;American Journal of Cancer Research;2024